Peregrine Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Peregrine Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	SELL	$39.16 - $88.71 $1.55 Million - $3.51 Million	-39,608 Closed	0 $0
Q1 2022 Apr 27, 2022	SELL	$75.82 - $150.97 $216,162 - $430,415	-2,851 Reduced 6.71%	39,608 $3.26 Million
Q4 2021 Jan 31, 2022	BUY	$132.01 - $190.29 $158,412 - $228,348	1,200 Added 2.91%	42,459 $6.23 Million
Q3 2021 Nov 02, 2021	SELL	$132.13 - $177.45 $3.16 Million - $4.24 Million	-23,902 Reduced 36.68%	41,259 $7.3 Million
Q2 2021 Aug 03, 2021	BUY	$144.0 - $179.73 $687,456 - $858,031	4,774 Added 7.91%	65,161 $10.5 Million

Q1 2021 May 11, 2021	BUY	$158.92 - $221.61 $9.6 Million - $13.4 Million	60,387 New	60,387 $10.3 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.